Avinger (NASDAQ:AVGR) Research Coverage Started at Aegis

Aegis started coverage on shares of Avinger (NASDAQ:AVGR) in a research report released on Thursday morning, The Fly reports. The brokerage issued a buy rating on the medical device company’s stock.

A number of other equities analysts also recently issued reports on AVGR. Zacks Investment Research raised shares of Avinger from a hold rating to a buy rating and set a $2.00 price target for the company in a research note on Tuesday, August 6th. ValuEngine downgraded shares of Avinger from a buy rating to a hold rating in a research note on Wednesday, September 4th.

Shares of NASDAQ:AVGR opened at $1.13 on Thursday. The company has a market cap of $7.26 million, a price-to-earnings ratio of -0.03 and a beta of 1.58. The company has a 50-day moving average price of $1.53 and a 200-day moving average price of $1.20. The company has a current ratio of 1.45, a quick ratio of 1.17 and a debt-to-equity ratio of 0.46. Avinger has a 12 month low of $1.04 and a 12 month high of $15.10.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings data on Wednesday, July 31st. The medical device company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.03. The firm had revenue of $2.32 million during the quarter. Avinger had a negative net margin of 258.12% and a negative return on equity of 230.13%. As a group, research analysts forecast that Avinger will post -2.61 EPS for the current fiscal year.

An institutional investor recently bought a new position in Avinger stock. Spark Investment Management LLC purchased a new position in Avinger Inc (NASDAQ:AVGR) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 103,043 shares of the medical device company’s stock, valued at approximately $98,000. Spark Investment Management LLC owned approximately 0.21% of Avinger at the end of the most recent reporting period. 7.51% of the stock is owned by hedge funds and other institutional investors.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Read More: Backdoor Roth IRA

The Fly

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.